Evidence map›Paper›PMID 26195695›Full record

ReviewJournal of clinical oncology : official journal of the American Society of Clinical Oncology2015

Second-Line Therapy for Endometrial Cancer: The Need for Better Options.

Gini F Fleming

Erratum issued Registry-linked trialAbstract readCase ReportsClinical ConferenceReview
PubMed Publisher
In one paragraph

Review in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03694262 (An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma), which is not on this map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03694262 phase2completednot on this mapstarted 2019, after this paper: background citation

An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma

TypeinterventionalSponsorMedical College of WisconsinRan2019 to 2026Enrolled30ConditionsEndometrial Cancer, Uterine CarcinosarcomaArmsRucaparib, Bevacizumab, Atezolizumab
3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Trial
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Gini F FlemingUniversity of Chicago, Chicago, IL gfleming@medicine.bsd.uchicago.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdenocarcinomaAminesAntineoplastic Combined Chemotherapy ProtocolsCarboplatinClinical Trials as TopicCyclohexanecarboxylic AcidsEndometrial NeoplasmsEstrogen Receptor alphaFemaleFluorouracilGabapentingamma-Aminobutyric AcidHumansMedical OncologyMiddle AgedPaclitaxelAminesCarboplatinCyclohexanecarboxylic AcidsESR1 protein, humanEstrogen Receptor alphaFluorouracilGabapentingamma-Aminobutyric AcidMTOR protein, humanPaclitaxelReceptors, ProgesteroneTOR Serine-Threonine Kinases

Identifiers

PMID26195695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.